Screener / SEC EDGAR /CIK 0001388658 /10-K filed Feb 19, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Instruments

iRhythm Holdings, Inc. IRTC

Compare with peers Embed
Planned sales, announced before they happen

7 trading plans running, 6 Form 144 notices for $1.9M

10-Q, 10-K and Form 144
Plans running now 7 Julie Rodda(2), Brian Yoor, Chad Patterson, Marc Rosenbaum, Mervin Smith, Bruce Bodaken, Abhijit Talwalkar
Plans adopted 16 reported since May 4, 2023 Form 144 notices 6 $1.9M the sellers expected to sell

What IRTC's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From May 5, 2025 to May 12, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
Julie Rodda(2)
EVP, Chief People & Capability Officer
Adopted 10b5-1 plan Dec 9, 2025 10-Q Apr 30, 2026
Brian Yoor
Director
Adopted 10b5-1 plan Dec 3, 2025 10-K Feb 19, 2026
Chad Patterson
Chief Commercial and Product Officer
Adopted 10b5-1 plan Dec 3, 2025 10-K Feb 19, 2026
Marc Rosenbaum
SVP, Chief Accounting Officer
Adopted 10b5-1 plan Nov 25, 2025 10-K Feb 19, 2026
Mervin Smith
Executive Vice President, Business Operations
Adopted 10b5-1 plan Nov 19, 2025 10-K Feb 19, 2026
Bruce Bodaken
Director
Adopted 10b5-1 plan Nov 17, 2025 10-K Feb 19, 2026
Sumi Shrishrimal
Executive Vice President, Chief Risk Officer
Adopted 10b5-1 plan May 23, 2025 10-Q Jul 31, 2025
Abhijit Talwalkar
Director
Adopted 10b5-1 plan May 12, 2025 10-Q Jul 31, 2025
Marc Rosenbaum
Senior Vice President, Chief Accounting Officer
Adopted 10b5-1 plan May 12, 2025 10-Q Jul 31, 2025
Mark Rubash
Director(2)
Adopted 10b5-1 plan May 5, 2025 10-Q Jul 31, 2025
Quentin Blackford
President and Chief Executive Officer
Adopted 10b5-1 plan May 5, 2025 10-Q Jul 31, 2025
Chad Patterson
Chief Commercial Officer
Adopted 10b5-1 plan Nov 25, 2024 10-K Feb 20, 2025
What the company wrote
On November 25, 2024, Chad Patterson, the Company's Chief Commercial Officer, entered into a prearranged written stock sale plan in accordance with Rule 10b5-1 (the “Patterson 10b5-1 Plan”) under the Exchange Act for the sale of shares of the Company's common stock. The Patterson 10b5-1 Plan was entered into during an open trading window in accordance with the Company’s policies regarding transactions in the Company’s securities and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The Patterson 10b5-1 Plan provides for the potential sale of up to 7,951 shares of the Company's common stock, including upon the vesting and settlement of restricted stock units and performance restricted stock units for shares of the Company's common stock, so long as the market price of the Company's common stock is higher than a certain minimum threshold prices specified in Patterson 10b5-1 Plan, between February 24, 2025 and December 2, 2025.
Daniel Wilson
Chief Financial Officer
Adopted 10b5-1 plan Nov 14, 2024 10-K Feb 20, 2025
What the company wrote
On November 14, 2024, Daniel Wilson, the Company's Chief Financial Officer, entered into a prearranged written stock sale plan in accordance with Rule 10b5-1 (the “Wilson 10b5-1 Plan”) under the Exchange Act for the sale of shares of the Company's common stock. The Wilson 10b5-1 Plan was entered into during an open trading window in accordance with the Company’s policies regarding transactions in the Company’s securities and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The Wilson 10b5-1 Plan provides for the potential sale of up to 18,000 shares of the Company's common stock, including upon the vesting and settlement of restricted stock units and performance restricted stock units for shares of the Company's common stock, so long as the market price of the Company's common stock is higher than a certain minimum threshold prices specified in Wilson 10b5-1 Plan, between March 3, 2025 and August 11, 2025.
Mark J. Day
Chief Technology Officer
Adopted 10b5-1 plan Mar 13, 2024 10-Q May 2, 2024
What the company wrote
On March 13, 2024, Mark J. Day, the Company's then Chief Technology Officer, entered into a prearranged written stock sale plan in accordance with Rule 10b5-1 (the “Day Rule 10b5-1 Plan”) under the Exchange Act for the sale of shares of the Company’s common stock. The Day Rule 10b5-1 Plan was entered into during an open trading window in accordance with the Company’s policies regarding transactions in the Company’s securities and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The Day Rule 10b5-1 Plan provides for the potential sale of up to 6,090 shares of the Company’s common stock, including upon the vesting and settlement of restricted stock units and performance restricted stock units for shares of the Company’s common stock, so long as the market price of the Company’s common stock is higher than certain minimum threshold prices specified in the Day Rule 10b5-1 Plan, between June 12, 2024 and March 13, 2025. The Day Rule 10b5-1 Plan includes a representation from Mr. Day to the broker administering the plan that he was not in possession of any material nonpublic information regarding the Company or the securities subject to the Day Rule 10b5-1 Plan at the time it was entered into. A similar representation was made to the Company in connection with the adoption of the Day Rule 10b5-1 Plan under the Company’s policies regarding transactions in the Company’s securities. Those representations were made as of the date of adoption of the Day Rule 10b5-1 Plan, and speak only as of such date. In making those representations, there is no assurance with respect to any material nonpublic information of which the insider was unaware, or with respect to any material nonpublic information acquired by the insider or the Company after the date of the representation.
Dan Wilson,
Company's Executive Vice President of Corporate Development and Investor Relations
Adopted 10b5-1 plan May 31, 2023 10-Q Aug 4, 2023
What the company wrote
On May 31, 2023, Dan Wilson, the Company's Executive Vice President of Corporate Development and Investor Relations, entered into a pre-arranged written stock sale plan in accordance with Rule 10b5-1 (the “Wilson Rule 10b5-1 Plan”) under the Exchange Act for the sale of shares of the Company’s common stock. The Wilson Rule 10b5-1 Plan was entered into during an open trading window in accordance with the Company’s policies regarding transactions in the Company’s securities and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The Wilson Rule 10b5-1 Plan provides for the potential sale of up to 20,706 shares of the Company’s common stock, including upon the vesting and settlement of restricted stock units and performance restricted stock units for shares of the Company’s common stock, so long as the market price of the Company’s common stock is higher than certain minimum threshold prices specified in the Wilson Rule 10b5-1 Plan, between August 22, 2023 and August 15, 2024.The Wilson Rule 10b5-1 Plan includes a representation from Mr. Wilson to the broker administering the plan that he was not in possession of any material nonpublic information regarding the Company or the securities subject to the Rule 10b5-1 Plan at the time it was entered into. A similar representation was made to the Company in connection with the adoption of the Wilson Rule 10b5-1 Plan under the Company’s policies regarding transactions in the Company’s securities. Those representations were made as of the date of adoption of the Wilson Rule 10b5-1 Plan, and speak only as of such date. In making those representations, there is no assurance with respect to any material nonpublic information of which the insider was unaware, or with respect to any material nonpublic information acquired by the insider or the Company after the date of the representation.
Bruce Bodaken
Director
Adopted plan – 10-Q Apr 30, 2026
Show the other 8 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 4, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
May 11, 2026 ABHIJIT Y TALWALKAR
Director
5,312 $626K
Mar 16, 2026 MERVIN SMITH
Officer
2,585 $295K
Feb 24, 2026 MERVIN SMITH
Officer
732 $103K
Feb 24, 2026 MARC ROSENBAUM
Officer
280 $39K
Feb 23, 2026 ABHIJIT Y TALWALKAR
Director
5,312 $774K
Dec 2, 2025 CHAD PATTERSON
Officer
280 $52K

From the Form 144 XML filed with the SEC, since Dec 2, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/IRTC/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.